Aveeno is owned by Kenvue (the United States, NYSE: KVUE), which was separated from Johnson & Johnson on 23 August 2023.[1][2] Before Kenvue, Aveeno was owned by Johnson & Johnson from 1999 to 2023.[2]
Aveeno is built around colloidal oatmeal, finely milled oats suspended in a bath preparation, first sold in 1945 for irritated skin. The name comes from the Latin for oats. Johnson & Johnson acquired the brand in 1999 and it transferred to Kenvue in the 2023 consumer health separation.
What Kenvue's annual report says about Aveeno
Sentences about Aveeno from Kenvue's latest annual filing[1], copied word for word.
The CID seeks documents related to certain Aveeno Baby products that are labelled as "hypoallergenic." Although we will produce documents and information responsive to the CID, efforts to ensure that we are and remain compliant with the various state consumer protection laws may involve substantial costs, and we cannot predict the outcome of any such investigations or their potential impact on our business.
How often Kenvue names Aveeno in its annual report
A plain count of the times the name appears in the text of each annual report, not counting the start of a sentence. A brand that an owner writes about more is usually one it treats as central. The brand is named less often than it was three years earlier.
Kenvue is a publicly listed company headquartered in Summit, New Jersey, United States, founded in 2023. Brandtree records 13 brands under its control, and it is listed as NYSE: KVUE.
Kenvue is the consumer health business separated from Johnson & Johnson, listed in May 2023 and fully split off that August. It holds the self-care, skin health and essential health brands that Johnson & Johnson had built up over a century. Kimberly-Clark agreed to acquire Kenvue in November 2025.
Brandtree records a controlling owner for 2,549 brands that began in the United States.
478 of them (19%) are now controlled by a company headquartered in another country; Aveeno is not one of them.
Kimberly-Clark agreed to acquire Kenvue for $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, which would combine Huggies and Kleenex with Tylenol, Listerine and Neutrogena. Kimberly-Clark expects to issue about 280 million shares and pay about $6.7 billion in cash, leaving its existing shareholders with about 54 per cent of the combined company.
Johnson & Johnson separated its consumer health business as Kenvue, which listed in May 2023 and was fully split off through an exchange offer completed on 23 August 2023. Tylenol, Band-Aid, Listerine, Neutrogena and Johnson's Baby all moved to the new company.
Brandtree needs to remember this choice and does not set any other cookie unless you accept.
If you choose “Accept all”, we also use Google Analytics cookies to count visits and see which pages help, so we can improve the site.
If you choose “Accept required”, no analytics cookie is set. Google Analytics still receives a cookieless ping with the page address and your IP address. No advertising is used either way. Privacy policy